• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Korea·Healthcare·268600.KQ
Share

Cellivery Therapeutics, Inc. Stocks

₩ 0Last Updated 23.03.2026

Issuer Rating

Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

₩ 163.93M

₩ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.08.2026 01:35

Tankers have resumed loading oil from Kazakhstan at a key terminal following the attacks

04.08.2026 00:26

Boeing has received regulatory approval for a smaller version of its most popular aircraft

03.08.2026 23:29

Shares of Cloud Giants Soared: Microsoft and Amazon Reassured Investors

03.08.2026 22:46

Earnings Reports from Palantir, SpaceX, and AMD Will Be a "Real-World Test" for the AI Rally — Saxo Bank

03.08.2026 22:30

The new "Spider-Man" brought AMC theaters record box office receipts in its 106-year history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026